MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Posted innews Oncology Urology

MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC

Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported quality of life, but did not demonstrate a statistically significant overall survival benefit in the primary analysis.
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Posted inDermatology news Oncology

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectable cutaneous squamous cell carcinoma.
Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma
Posted innews Oncology

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma

The randomized phase 1b/2 Morpheus‑Melanoma trial found that tobemstomig (anti‑PD‑1/anti‑LAG‑3 bispecific) produced comparable pathological response rates to nivolumab plus ipilimumab with a substantially improved safety profile in resectable stage III melanoma.
Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Posted inNeurology news Oncology

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.
Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
Posted inDermatology news Oncology

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism

A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a two‑hit, T‑cell–mediated model and urging cautious coprescribing and prospective study.
Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report
Posted inHematology-Oncology news

Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report

CIBMTR's 2013–2023 registry update shows a 2023 rebound in allogeneic HCT—driven by older adults—widespread adoption of post‑transplant cyclophosphamide (PTCy) across donor types, increasing mismatched donor use, and rapid expansion of commercial CAR‑T therapy; relapse remains the leading cause of death.
Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide
Posted inHematology-Oncology news

Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide

In CMV‑seronegative adult AML recipients receiving unrelated donor hematopoietic cell transplantation with PTCy, donor CMV seropositivity was associated with worse overall survival—primarily through a trend toward higher relapse—supporting consideration of donor CMV serostatus in selection.